Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

NCT06347458 is registered in ClinicalTrials.gov with Guangzhou Bio-gene Technology Co., Ltd as lead sponsor.

NCT NCT06347458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06347458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Dose-escalation and Dose-expansion Phase I Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
Lead sponsor
Guangzhou Bio-gene Technology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2024
Completion date
August 31, 2027
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, leukemia